Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.51 |
| ▸ | POLA1 | P09884 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713746 | 0.87 | EGLN1 (0.43) | EGLN1POLA1HPGDCYP1A2CYP2C19 | |
| SCHEMBL6669962 | 0.81 | EGLN1 (0.44) | EGLN1POLA1HPGDCYP1A2CYP2C19 | |
| SCHEMBL6717283 | 0.80 | MAPK8 (0.44) | EGLN1POLA1HPGDCYP1A1NR3C1 | |
| SCHEMBL6286401 | 0.77 | MAPT (0.54) | — | |
| SCHEMBL6196625 | 0.77 | NR3C1 (0.44) | EGLN1POLA1HPGDCYP1A2CYP2C19 | |
| SCHEMBL6669782 | 0.77 | EGLN1 (0.50) | EGLN1POLA1HPGDCYP1A2CYP2C19 | |
| SCHEMBL6197455 | 0.77 | NR3C1 (0.44) | EGLN1POLA1HPGDCYP1A2CYP2C19 | |
| SCHEMBL6699580 | 0.77 | EGLN1 (0.43) | EGLN1POLA1HPGDCYP1A1NR3C1 | |
| SCHEMBL6707963 | 0.76 | SMN1; SMN2 (0.44) | EGLN1POLA1HPGDCYP1A2CYP2C19 | |
| SCHEMBL6287132 | 0.75 | MEN1 (0.43) | HPGDCYP1A2CYP2C19CYP2C9NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| US-6562822-B2 | Heterocyle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | claimed |
| EP-1299360-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| US-20020188004-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-12-12 | — | — | US | claimed |
| WO-2002004422-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6562822-B2 | Heterocyle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | EGLN1 1486/4885POLA1 2447/4885HPGD 387/4885 |
| US-20020188004-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | EGLN1 134/4885POLA1 267/4885HPGD 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.